JP2008546672A5 - - Google Patents

Download PDF

Info

Publication number
JP2008546672A5
JP2008546672A5 JP2008516350A JP2008516350A JP2008546672A5 JP 2008546672 A5 JP2008546672 A5 JP 2008546672A5 JP 2008516350 A JP2008516350 A JP 2008516350A JP 2008516350 A JP2008516350 A JP 2008516350A JP 2008546672 A5 JP2008546672 A5 JP 2008546672A5
Authority
JP
Japan
Prior art keywords
ifn
pharmaceutical composition
sequence encoding
family cytokine
pegylated
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2008516350A
Other languages
English (en)
Japanese (ja)
Other versions
JP5154412B2 (ja
JP2008546672A (ja
Filing date
Publication date
Priority claimed from ES200501468A external-priority patent/ES2302402B1/es
Application filed filed Critical
Publication of JP2008546672A publication Critical patent/JP2008546672A/ja
Publication of JP2008546672A5 publication Critical patent/JP2008546672A5/ja
Application granted granted Critical
Publication of JP5154412B2 publication Critical patent/JP5154412B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2008516350A 2005-06-16 2006-06-16 インターフェロンアルファとの組み合わせ投与のための組成物の調製における、インターロイキン６ファミリーサイトカインの使用 Expired - Fee Related JP5154412B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
ES200501468A ES2302402B1 (es) 2005-06-16 2005-06-16 Uso de una citoquina de la familia de interleuquina-6 en la preparacion de una composicion para administracion combinada con interferon-alfa.
ESP200501468 2005-06-16
PCT/ES2006/000353 WO2006134195A2 (es) 2005-06-16 2006-06-16 Uso de una citoquina de la familia de interleuquina-6 en la preparación de una composición para administración combinada con interperón-alfa

Publications (3)

Publication Number Publication Date
JP2008546672A JP2008546672A (ja) 2008-12-25
JP2008546672A5 true JP2008546672A5 (enExample) 2012-11-29
JP5154412B2 JP5154412B2 (ja) 2013-02-27

Family

ID=37532659

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2008516350A Expired - Fee Related JP5154412B2 (ja) 2005-06-16 2006-06-16 インターフェロンアルファとの組み合わせ投与のための組成物の調製における、インターロイキン６ファミリーサイトカインの使用

Country Status (11)

Country Link
US (2) US7829077B2 (enExample)
EP (1) EP1905447A4 (enExample)
JP (1) JP5154412B2 (enExample)
CN (1) CN101257918B (enExample)
AU (1) AU2006258966B8 (enExample)
BR (1) BRPI0611988A2 (enExample)
CA (1) CA2612282C (enExample)
ES (1) ES2302402B1 (enExample)
MX (1) MX2007016060A (enExample)
RU (1) RU2413529C2 (enExample)
WO (1) WO2006134195A2 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA106591C2 (uk) * 2008-07-23 2014-09-25 Тамара Алєксандровна Віткалова Спосіб лікування гепатиту с з використанням інтерферону та інтерлейкіну-1
JP2010059081A (ja) * 2008-09-02 2010-03-18 Okayama Univ オンコスタチンｍを含有する抗ｈｃｖ剤およびその利用
ES2342529B1 (es) * 2008-10-07 2011-05-11 Proyecto De Biomedicina Cima, S.L. Oncostatina m como potenciador de la actividad inmunoestimuladora de celulas epiteliales humanas.
US20120308517A1 (en) * 2010-02-09 2012-12-06 Digna Biotech, S.L. Compositions for the treatment of infectious and tumoural diseases
WO2017197036A1 (en) 2016-05-10 2017-11-16 C4 Therapeutics, Inc. Spirocyclic degronimers for target protein degradation
WO2017197051A1 (en) 2016-05-10 2017-11-16 C4 Therapeutics, Inc. Amine-linked c3-glutarimide degronimers for target protein degradation
EP3454856B1 (en) 2016-05-10 2024-09-11 C4 Therapeutics, Inc. Heterocyclic degronimers for target protein degradation
EP3455218A4 (en) 2016-05-10 2019-12-18 C4 Therapeutics, Inc. C3 CARBON-BASED GLUTARIMIDE DEGRONIMERS FOR TARGET PROTEIN REDUCTION
JP7264867B2 (ja) 2017-03-31 2023-04-25 アッカニス・バイオテック・エフ・アンド・イー・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング・ウント・コムパニー・コマンディットゲゼルシャフト 非メラノーマ皮膚癌（ｎｍｓｃ）の予防および治療
CN110769822A (zh) 2017-06-20 2020-02-07 C4医药公司 用于蛋白降解的n/o-连接的降解决定子和降解决定子体
CN113197910B (zh) * 2021-05-14 2022-09-23 苏州大学 一种基于阿司匹林及其代谢产物提高干扰素抗病毒活性的抗病毒药盒

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE67035B1 (en) * 1986-07-08 1996-02-21 Genetics Inst Production and use of non-glycosylated IL-6
US6284237B1 (en) 1986-07-08 2001-09-04 Steven C. Clark Methods of treatment using IL-6
US6348191B1 (en) 1986-07-08 2002-02-19 Genetics Institute, Inc. Production and use of IL-6
US5372808A (en) * 1990-10-17 1994-12-13 Amgen Inc. Methods and compositions for the treatment of diseases with consensus interferon while reducing side effect
US5766582A (en) 1994-10-11 1998-06-16 Schering Corporation Stable, aqueous alfa interferon solution formulations
JP2758154B2 (ja) 1995-04-06 1998-05-28 エフ・ホフマン−ラ ロシユ アーゲー インターフェロンを含む液体製剤
US5908621A (en) 1995-11-02 1999-06-01 Schering Corporation Polyethylene glycol modified interferon therapy
CA2329474C (en) * 1995-11-02 2002-02-26 Schering Corporation Continuous low-dose cytokine infusion therapy
GB9609932D0 (en) * 1996-05-13 1996-07-17 Hoffmann La Roche Use of IL-12 and IFN alpha for the treatment of infectious diseases
EP1860192A1 (en) * 1996-09-17 2007-11-28 Novartis Vaccines and Diagnostics, Inc. Compositions and methods for treating intracellular diseases
AR013269A1 (es) * 1997-08-04 2000-12-13 Scras Producto que contiene por lo menos un rna de doble filamento combinado con por lo menos un agente anti-viral, para la utilizacion terapeutica en eltratamiento de una enfermedad viral, en especial de la hepatitis viral
AU2158000A (en) 1998-12-22 2000-07-12 Schering Corporation Treatment of hepatitis c virus infections with interleukin-10
ES2200646B1 (es) * 2001-09-21 2005-05-01 Fundacion Para La Investigacion Medica Aplicada Uso de la cardiotrofina en enfermedades hepaticas.
TW200408407A (en) * 2001-11-30 2004-06-01 Dana Farber Cancer Inst Inc Methods and compositions for modulating the immune system and uses thereof
RU2222345C2 (ru) * 2002-01-21 2004-01-27 Волчек Игорь Анатольевич Фармацевтическая композиция цитокинового и иммуномодулирующего действия
US20050027110A1 (en) * 2003-07-24 2005-02-03 Michael Russell Drug delivery in the nervous system

Similar Documents

Publication Publication Date Title
Lin et al. Interferons: Success in anti-viral immunotherapy
Gao Cytokines, STATs and liver disease
Perry et al. Peginterferon-α-2a (40kD) A review of its use in the management of chronic hepatitis C
JP2008546672A5 (enExample)
El-Baky et al. Therapeutic alpha-interferons protein: structure, production, and biosimilar
JP2008513356A5 (enExample)
CA2573207A1 (en) Use of a combination of cyclosporin and pegylated interferons for treating hepatitis c (hcv)
US20110027224A1 (en) Use of a cytokine from the interleukin-6 family in the preparation of a composition for combined administration with interferon-alpha
CN1764475A (zh) 治疗病毒性疾病和肝纤维化的干扰素药物治疗
EP2739301A1 (en) Hcv immunotherapy
EP2535057A2 (en) Compositions for the treatment of infectious and tumoural diseases
Chronopoulou et al. Interferon Lambda: The Next Frontier in Antiviral Therapy?
Nishimura et al. Acute onset of nephrotic syndrome during interferon-α retreatment for chronic active hepatitis C
CA2627531A1 (en) Interferon-alpha and c-phycocyanin for the treatment of autoimmune diseases, allergic diseases and cancer
AU2005221710A1 (en) Pharmaceutical compositions comprising interferon-tau
Brown Jr et al. 41 Differences in treatment outcome to antiviral therapy based on genotype and viral load in hepatitis C genotypes 2 and 3 in the Win-R trial
Clark et al. Novel interferons for treatment of hepatitis C virus
Witthoeft et al. [655] PEG-IFN ALFA-2a PLUS RIBAVIRIN IS SUPERIOR COMPARED TO HIGH DOSE CONSENSUS INTERFERON (CIFN) AND RIBAVIRIN IN THE TREATMENT OF PATIENTS WITH CHRONIC HEPATITIS C
JPWO2004083186A1 (ja) ウイルス性肝炎治療剤及び制癌剤
Dev et al. Current standard of care in hepatitis C virus infection
Piguet et al. 42 The mitochondrial AMP-lysine hydrolase, HINT2, sensitizes experimental hepatocellular carcinoma to FAS-induced apoptosis
Young Clinical Use of Interferon-y
Abramowicz Peginterferon alfa-2A (Pegasys) for chronic hepatitis C
Tacke LETTER TO
Zehnter et al. [656] THE ROLE OF GLOMERULAR FILTRATION RATE (GFR) FOR TREATMENT WITH PEGINTERFERON ALFA 2a (PEG) AND RIBAVIRIN (RBV) IN PATIENTS WITH CHRONIC HEPATITIS C (CHC)